JPMorgan raised the firm’s price target on PTC Therapeutics (PTCT) to $68 from $67 and keeps an Overweight rating on the shares. The firm’s checks with physicians and payer access experts indicate solid demand for Sephience in phenylketonuria.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics (PTCT) Q2 Earnings Cheat Sheet
- PTC Therapeutics’ Future at Risk: Navigating Operational and Financial Challenges
- PTC Therapeutics price target raised to $84 from $68 at BofA
- PTC Therapeutics Receives Buy Rating Following FDA Approval of Sephience and Strategic Market Positioning
- PTC Therapeutics price target raised to $86 from $80 at Truist